dc.contributor.author | Aucoin, Monique et al. | |
dc.date.accessioned | 2020-09-21T18:40:39Z | |
dc.date.available | 2020-09-21T18:40:39Z | |
dc.date.issued | 2020-07-30 | |
dc.identifier.uri | 10.1016/j.aimed.2020.07.007 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/2181 | |
dc.description.abstract | Brief overview: There is currently insufficient evidence to recommend quercetin supplementation as a therapy for the treatment or prevention of COVID-19. Three human clinical trials with low risk of bias suggest that oral quercetin may have a beneficial effect on the incidence and duration of respiratory tract infections in certain populations; however, further research is needed.
Verdict: Current evidence on the efficacy of quercetin supplementation in the treatment and prevention of COVID-19 is insufficient for its clinical recommendation at this time. Quercetin exhibits both immunomodulatory and antimicrobial effects in preclinical studies; however, only three human clinical trials, each with a low risk of bias rating, were identified in this rapid review. One study reported a decrease in incidence of upper respiratory tract infections following a competitive athletic event. A larger community clinical trial reported a benefit in older, athletic adults only. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus Infections | en_US |
dc.subject | Quercetin | en_US |
dc.subject | Respiratory Tract Infections | en_US |
dc.subject | Systematic Review | en_US |
dc.title | The effect of quercetin on the prevention or treatment of COVID-19 and other respiratory tract infections in humans: A rapid review | en_US |
eihealth.country | Others | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | Adv Integr Med | en_US |